23.12.2020 | Seasons Greetings
An unusual year is coming to an end. We are all richer by many experiences. We would like to take this opportunity to thank you: for the conversations we were able to have with you in 2020, for your trust and your partnership.
We look forward to the new year with confidence and have one goal in mind: preserving vision through transcorneal electrical stimulation!
We wish everyone a Merry Christmas and a healthy and fulfilling New Year.
18.11.2020 | New Competence Centres
We are extending our netwrok in Germany and Austria
We are very pleased to welcome two new Competence Centres in our network of partners.
The University Eye Clinic Leipzig and the Eye Clinic of Kepler University Linz have opened
their doors to you.
We hope to be getting closer to you and wish you a beautiful autumn.
Yours, Okuvision GmbH
16.07.2020 | Clinical Trial Underway
Federal Joint Committee commissions large scale clinical investigation of TES for RP
With the press release on 16th July it became official: following a Europe-wide tender, the Federal Joint Committee (G-BA) has commissioned the University Hospital Tübingen with the planning and scientific administration and evaluation of the forthcoming clinical investigation of transcorneal electrical stimulation for retinopathia pigmentosa (RP).
As a first step, the study protocol will be prepared, followed by obtainig ethics and administrative approvals and recruitment of the paticipating eye-hopsitals.
We will keep you up-to-date with all relevant developments.
Until then, we wish you a pleasant summer.
27.04.2020 | CE-Marking for the OkuStim® System
The time of uncertainty is over
We are pleased to inform you that our OkuStim system has again a valid CE marking and that we will resume sales, immediately.
Since we have used of the interim to produce large quantities of OkuEl electrodes, users who have pre-ordered electrodes will now be supplied very soon.
On behalf of the whole Okuvision team we would like to thank you very much for your patience and your trust. We are always available to answer your questions. We would be happy to hear from you and give you a perspective in your individual situation with TES therapy.
Dr. Alfred Stett
10.01.2020 | Okuvision in the new decade
New Year's resolution: new electrodes and devices
Our very best wishes for 2020. The new year begins with the good news that Okuvision is ready to deliver.
Before Christmas, however, it transpired that the CE certification of our products would take more time. It is now clear that it will be slightly longer than we were able to foresee in before the holidays.
To fulfill all regualtory requirements in the quickest way possible, we are in close exchange with the Notified Body in clarification of the outstanding questions. We will keep you informed about the progress.
In the past year we have done what we could in order to avoid any bigger supply shortages and we would like to thank our partners and users once again for their understanding and patience. Alas, it might now, be unvoidable that some therapy users run out of electrodes.
The shipment of new electrodes and devices will definitely resume immediately after issue of the CE mark. We deeply regret that we have to aks you for a little more patience.
We wish you a happy and prosperous 2020 abd look forward to hearing from you.
19.12.2019 | Okuvision at end of 2019
A joyous festive season and a prosperous new year
Okuvision GmbH is looking back on an exciting year of reformation and rebuilding. We are glad to be able to say that we have reached all the goals we could influence the outcomes of. Unfortunately, however, the CE certification could not be concluded before the end of the year .
The majority of our clinical and distribution partners are now officially back and we look forward to 2019 with anticipation.
Over the last few months we had the opportunity to talk to many existing and prospective users of our TES-therapy, which gave us deep insight into their individual needs and requirements. This will have a significant impact on our work in the future.
We would like to take this opportunity to thank all our active therapy users, people interested in the therapy as well as our partners at the Competence Centres and Opticians for your trust and patience.
We wish you all a joyous festive season and a happy and prosperous new year.
10.10.2019 | Okuvision in Autumn
First partners on board. PRO Retina and Okuvision in Berlin.
While we concentrate almost all efforts on the preparation for the audit to regain CE-certification at the end of the month, there are already some good news about our partners: most of our OkuStim Competence Centres will continue to be at your service.
Should you consider whether the electrostimulation therapie is an option for you, don't hesitate to get in touch with us via email (firstname.lastname@example.org) or via telephone on +49 (0) 7121 159350 and we will let you know the nearest centre for you, where you can start making an appointment as of now.
Moreover, you still have a chance to meet us and get some first-hand information abour the electrostimulation therapy with the OkuStim System this Autumn. Okuvision will be present at the PRO RETINA RP-Patient Symposium in Berlin on 9th November, where Prof. Klaus Rüther will speak about the therapy. You can find further information about the event (in German) here.
For all active users, OkuEl electrodes will remain available from Strebel-Hiltwein Optik in Tübingen.
03.09.2019 | Okuvision GmbH has moved
New address and certification underway
After a successful relaunch in June OKUVISION GmbH has now taken up operations at their new headquarter in Aspenhaustraße 25 in Reutlingen.
Our eleven-strong team is currently working hard get the company ready for successful auditing and new CE certification. We expect that we will be able to offer the OkuStim system and consumables again from the end of the year. At the same time, we are rebuilding our sales structures and network of partners in order to ensure a gapless supply for existing and new therapy users.
Until then, OkuEl elektrodes will remain available from Strebel-Hiltwein Optik in Tübingen. Contact: email@example.com; +49 (0) 7071 367076.
We would like to take this opportunity to thank all current and prospective users and our partners, the low-vision opticians and clinics, for their patience and trust. We are looking forward being able to offer you our system for transcorneal electrostimulation therapy again soon.
If you wish, we would be happy to keep you personally updated with newsletters on the latest developments at OKUVISION. Simply send an e-mail to firstname.lastname@example.org. Of course, we will be updating this website regularly.
03.06.2019 | Okuvision GmbH relaunches
Supply of transcorneal electrical stimulation (TES) is ensured
Following the announcement in March that with the liquidation of RETINA IMPLANT AG the supply of the OkuStim® therapy system for transcorneal electrostimulation (TES) will also be discontinued, patients and active users, as well as many clinics, ophthalmologists, and some patient associations, have reacted disappointed and sometimes emotionally. It became very clear that due to the lack of alternative treatment options and sources of supply there is a recognisable demand for the OkuStim® therapy system.
This intense response has resulted in an intensive discussion among the team and their supporters how the supply of the Okustim® therapy system can be ensured. We are very pleased that there is now a concrete answer to this question:
Formerly an independent company and integrated into RETINA IMPLANT AG in spring 2017, OKUVISION GmbH is currently being relaunched. With the help of an investor, OKUVISION GmbH will ensure the supply of the OkuStim® therapy system and consumables. We plan to have the production reopened and validated at a new location, by October, to facilitate a successful audit and new CE-certification. Former members of RETINA IMPLANT staff have been won for the new task at OKUVISION GmbH and our team is ready for the new beginning.
Most importantly: thanks to the extraordinary commitment of our production team, it has been possible to produce such a large quantity of electrodes in the recent weeks that the supply of active users should be secured for the coming half-year.
This provides us with the time necessary to rebuild OKUVISION GmbH. We expect to require about 6 months until we have everything up and running and can also offer the OkuStim® system to new users.
We are very excited and grateful for this opportunity, especially in regard to the many people affected by retinitis pigmentosa and the fact that transcorneal electrostimulation is one of the few, if not the only, meaningful therapeutic approach available to people affected by RP today and for the foreseeable future.
Dr. Alfred Stett